Lyme borreliosis in Belgium: a cost-of-illness analysis.
Belgium
Disseminated Lyme borreliosis
Economic cost
Erythema migrans
Late Lyme borreliosis
Lyme borreliosis
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
28 11 2022
28 11 2022
Historique:
received:
19
01
2022
accepted:
14
10
2022
entrez:
29
11
2022
pubmed:
30
11
2022
medline:
1
12
2022
Statut:
epublish
Résumé
Lyme borreliosis (LB) is the most common tick-borne disease in Europe and North America, yet its economic burden remains largely unknown. This study aimed to estimate the economic cost associated with the different clinical manifestations of LB in Belgium. An incidence approach and societal perspective were used to estimate the total cost-of-illness for LB in Belgium. Costs were calculated for patients with erythema migrans (EM) or disseminated/late LB, including patients who developed post-treatment Lyme disease syndrome (PTLDS). Direct medical, direct non-medical (transportation & paid help) and indirect non-medical costs (productivity losses) were included in the analysis. Ambulatory cost data were collected through a prospective cohort study from June 2016 to March 2020, in which patients with LB were followed up 6 to 12 months after diagnosis. Hospitalization costs were retrieved from the Minimal Clinical Data registry, a mandatory registry for all Belgian hospitals, linked to the Minimal Financial Data registry. Costs were expressed in 2019 euros. The total annual cost associated with clinical manifestations of LB in Belgium was estimated at €5.59 million (95% UI 3.82-7.98). Of these, €3.44 million (95% UI 2.05-5.48) or 62% was related to disseminated/late LB diagnoses and €2.15 million (95% UI 1.30-3.26) to EM. In general, direct medical costs and productivity losses accounted for 49.8% and 46.4% of the total costs, respectively, while direct non-medical costs accounted for only 3.8%. The estimated mean costs were €193 per EM patient and €5,148 per disseminated/late LB patient. While patients with PTLDS seemed to have somewhat higher costs compared to patients without PTLDS, the number of patients was too small to have representative estimates. We estimate the total annual direct medical costs, direct non-medical and indirect non-medical costs associated with LB to exceed €5.5 million per year, almost evenly distributed between EM (40%) and disseminated/late LB (60%). EM costs 26 times less per patient but occurs also 16 times more frequently than disseminated/late LB. The cost burden remains limited by comparison to other infectious diseases due to the relative lower incidence.
Sections du résumé
BACKGROUND
Lyme borreliosis (LB) is the most common tick-borne disease in Europe and North America, yet its economic burden remains largely unknown. This study aimed to estimate the economic cost associated with the different clinical manifestations of LB in Belgium.
METHODS
An incidence approach and societal perspective were used to estimate the total cost-of-illness for LB in Belgium. Costs were calculated for patients with erythema migrans (EM) or disseminated/late LB, including patients who developed post-treatment Lyme disease syndrome (PTLDS). Direct medical, direct non-medical (transportation & paid help) and indirect non-medical costs (productivity losses) were included in the analysis. Ambulatory cost data were collected through a prospective cohort study from June 2016 to March 2020, in which patients with LB were followed up 6 to 12 months after diagnosis. Hospitalization costs were retrieved from the Minimal Clinical Data registry, a mandatory registry for all Belgian hospitals, linked to the Minimal Financial Data registry. Costs were expressed in 2019 euros.
RESULTS
The total annual cost associated with clinical manifestations of LB in Belgium was estimated at €5.59 million (95% UI 3.82-7.98). Of these, €3.44 million (95% UI 2.05-5.48) or 62% was related to disseminated/late LB diagnoses and €2.15 million (95% UI 1.30-3.26) to EM. In general, direct medical costs and productivity losses accounted for 49.8% and 46.4% of the total costs, respectively, while direct non-medical costs accounted for only 3.8%. The estimated mean costs were €193 per EM patient and €5,148 per disseminated/late LB patient. While patients with PTLDS seemed to have somewhat higher costs compared to patients without PTLDS, the number of patients was too small to have representative estimates.
CONCLUSIONS
We estimate the total annual direct medical costs, direct non-medical and indirect non-medical costs associated with LB to exceed €5.5 million per year, almost evenly distributed between EM (40%) and disseminated/late LB (60%). EM costs 26 times less per patient but occurs also 16 times more frequently than disseminated/late LB. The cost burden remains limited by comparison to other infectious diseases due to the relative lower incidence.
Identifiants
pubmed: 36443755
doi: 10.1186/s12889-022-14380-6
pii: 10.1186/s12889-022-14380-6
pmc: PMC9703731
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2194Informations de copyright
© 2022. The Author(s).
Références
Ticks Tick Borne Dis. 2015 Feb;6(1):56-62
pubmed: 25448420
Public Health. 2003 Jul;117(4):264-73
pubmed: 12966749
Clin Infect Dis. 2006 Nov 1;43(9):1089-134
pubmed: 17029130
J Med Econ. 2008;11(1):135-50
pubmed: 19450115
Emerg Infect Dis. 2006 Apr;12(4):653-60
pubmed: 16704815
Health Aff (Millwood). 2019 Jan;38(1):87-95
pubmed: 30615520
Infect Genet Evol. 2016 Aug;42:66-76
pubmed: 27125686
Ticks Tick Borne Dis. 2019 Apr;10(3):598-605
pubmed: 30772196
Clin Microbiol Infect. 2010 Aug;16(8):1245-51
pubmed: 19793326
Health Policy. 2009 Oct;92(2-3):276-87
pubmed: 19505743
BMJ. 2020 May 26;369:m1041
pubmed: 32457042
Nat Rev Dis Primers. 2016 Dec 15;2:16090
pubmed: 27976670
Eur J Pediatr. 2008 Dec;167(12):1409-19
pubmed: 18317802
Arch Public Health. 2017 Aug 7;75:42
pubmed: 28794875
Can Commun Dis Rep. 2018 Oct 04;44(10):243-256
pubmed: 31524886
Vaccine. 2012 Sep 14;30(42):6070-80
pubmed: 22858555
PLoS One. 2019 Jan 4;14(1):e0210280
pubmed: 30608986
Epidemiol Infect. 2012 Nov;140(11):2096-109
pubmed: 22230041
Lancet. 2012 Feb 4;379(9814):461-73
pubmed: 21903253
Eur J Public Health. 2017 Jun 1;27(3):538-547
pubmed: 28444236
BMC Public Health. 2021 Jan 22;21(1):192
pubmed: 33482767
Clin Ther. 1998 Sep-Oct;20(5):993-1008; discussion 992
pubmed: 9829450
BMC Infect Dis. 2022 Sep 28;22(1):756
pubmed: 36171561